LOGIN
Tanezumab effectively and safely reduces OA hip pain and improves physical function
October 2013
Tanezumab effectively and safely reduces OA hip pain and improves physical function
Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A
Tanezumab Reduces Osteoarthritic Hip Pain: Results of a Randomized, Double-Blind, Placebo-Controlled Phase III Trial
Arthritis Rheum. 2013 Jul;65(7):1795-803. doi: 10.1002/art.37950Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
627 patients with hip osteoarthritis (OA) were randomized to receive either 2.5 mg, 5 mg, or 10 mg doses of intravenous tanezumab (monoclonal antibody against nerve growth factor) or a placebo. The purpose was to compare each treatment's efficacy in lowering pain. After 32 weeks, results indicated that patients who were treated with tanezumab had significantly greater improvements in pain and phys...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
The OE High Impact metric uses AI to determine the impact a study will have by considering the content of the article itself. Built using the latest advances of natural language processing techniques. OE High Impact predicts an article’s future number of citations than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.